Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Chemotherapy, Adjuvant MeSH
- Ki-67 Antigen analysis MeSH
- Cyclophosphamide therapeutic use MeSH
- Doxorubicin therapeutic use MeSH
- Fluorouracil therapeutic use MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Breast Neoplasms drug therapy immunology metabolism MeSH
- Neoadjuvant Therapy * MeSH
- Prognosis MeSH
- Receptor, ErbB-2 analysis MeSH
- Receptors, Estrogen analysis MeSH
- Receptors, Progesterone analysis MeSH
- Taxoids therapeutic use MeSH
- Trastuzumab MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Ki-67 Antigen MeSH
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- ERBB2 protein, human MeSH Browser
- Fluorouracil MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Biomarkers, Tumor MeSH
- Receptor, ErbB-2 MeSH
- Receptors, Estrogen MeSH
- Receptors, Progesterone MeSH
- Taxoids MeSH
- Trastuzumab MeSH
Neoadjuvant chemotherapy (NCT) of breast cancer enabled improved outcomes especially in patients with advanced and inflammatory diseases. Biological heterogeneity of these tumors, however, requires better molecular characterization of the malignant tissue with consequent individualization in the selection of appropriate agents. To date, numerous molecular markers have been identified, and some of them (e.g., measurement of hormonal or growth factors receptors) are already routinely used for breast cancer classification before NCT. In the present article, we summarize current knowledge about established as well as promising biomarkers which have demonstrated prognostic or predictive value in NCT of breast cancer.
References provided by Crossref.org
